Academic / Industrial Partnership Opportunities

Due to Sosei Heptares’ renewed focus on small molecules and therapeutic antibodies, a number of active programs have been set aside for academic or industrial partnerships and will not be progressed any further by Sosei Heptares In-House on a fully-funded basis. These programs are outlined briefly below with links to a more detailed description of the program status and rationale. Academics or other interested parties should contact Sosei Heptares at BusDev@SoseiHeptares.com to discuss potential partnerships or for provision of test materials for experimental studies. In each case, there is a clear intellectual property positioning and the assets can also be made available under licence.

Programs available for Partnering

PHASE 1

SSTR5 agonist

CANDIDATE: HTL'310

INDICATION: Hypoglycaemic disorders

MODALITY: Peptide

Cyclic peptide with selectivity for somatostatin 5 receptor which has been studied is a Phase 1 clinical trial via subcutaneous dosing. Demonstrated dose dependent effects on glucose homeostasis and therefore of potential utility for treatment of hypoglycaemic disorders.

+ Program Overview

Preclinical

GLP-1 antagonist

CANDIDATE: HTL'097

INDICATION: Hypoglycaemic disorders

MODALITY: Peptide

Linear truncated peptide, a selective and potent GLP1 receptor antagonist. Robust preclinical package supporting further development as a treatment for hypoglycaemic disorders, administered by subcutaneous injection.

+ Program Overview

Preclinical

Dual GLP-2/GLP-1 agonist

CANDIDATE: HTL'023

INDICATION: Intestinal failure and/or NASH

MODALITY: Peptide

Linear peptide, a modified derivative of the GLP2 hormone, acting as a dual GLP2 / GLP1 agonist with picomolar potency. Extensive preclinical package supporting use in intestinal failure and/or fatty liver disease (NASH) with an improved profile over either a selective GLP2 or selective GLP1 agonist in benchmarking studies.

+ Program Overview

Discovery

Apelin agonist

INDICATION: Pulmonary Arterial Hypertension

MODALITY: Peptide

A number of apelin agonist peptides have been studied in preclinical models to establish the role of signalling bias. A lead peptide has been selected which has the potential for further development for the treatment of pulmonary arterial hypertension.

+ Program Overview

Discovery

Dual Orexin antagonist

CANDIDATE: HTL'641

INDICATION: Insomnia and sleep disorders

MODALITY: Small molecule

A dual orexin 1 / orexin 2 antagonist has been selected as a preclinical candidate and is outlined in the below publication. Dual orexin antagonists such as suvorexant and Lemborexant have been demonstrated to have broad utility in the treatment of sleep disorders.

+ Publications